254,845 Shares in PROCEPT BioRobotics Corporation $PRCT Bought by Man Group plc

Man Group plc purchased a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 254,845 shares of the company’s stock, valued at approximately $5,754,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Versant Capital Management Inc boosted its stake in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after acquiring an additional 1,084 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares in the last quarter. Center for Financial Planning Inc. acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at about $40,000. Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the first quarter worth about $42,000. Finally, Essential Partners LLC lifted its position in shares of PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after purchasing an additional 1,980 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Evercore set a $23.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. UBS Group cut shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a report on Tuesday, July 28th. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, Leerink Partners downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $31.00 to $29.00 in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
• Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
• Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

PROCEPT BioRobotics Stock Up 1.1%

Shares of PROCEPT BioRobotics stock opened at $20.83 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $42.43. The business’s fifty day moving average price is $20.32 and its two-hundred day moving average price is $23.93. The company has a market capitalization of $1.19 billion, a P/E ratio of -10.74 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.35) EPS. As a group, research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood purchased 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares in the company, valued at $498,315. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.